Literature DB >> 21641848

Subclinical signs in LRRK2 mutation carriers.

Krisztina K Johansen1, Linda R White, Matthew J Farrer, Jan O Aasly.   

Abstract

BACKGROUND: Several non-motor features have been reported to precede the motor signs of Parkinson's disease (PD) by several years. However, the time of onset of non-motor and motor symptoms is still debated. Healthy individuals carrying a PD-related mutation are candidates for studying the earliest disease signs.
OBJECTIVES: To describe clinically healthy family members of PD patients carrying a LRRK2 mutation (LRRK2-PD).
METHODS: A total of 47 family members of LRRK2-PD patients were included in the present study and were screened for the p.G2019S and p.N1437H substitutions in the LRRK2 gene. A standardized case report form was filled out in each case, including general medical evaluation, neurological examination with UPDRS, an olfaction test, mood, sleep and cognitive questionnaires.
RESULTS: Thirty-two study participants were positive, and 15 were negative for a LRRK2 mutation. Higher UPDRS motor scores, more frequent reports of urinary problems, and fewer hours of sleep were found in mutation carriers compared to non-carriers. The mutation carriers with UPDRS ≥8 were all aged over 50 years, had shorter overall sleeping hours, more frequent urinary and constipation problems, higher mood scores and body mass index. Deterioration of olfaction was not detected in either group.
CONCLUSION: Healthy LRRK2 mutation carriers presented subclinical parkinsonian motor and non-motor signs in the apparent absence of olfactory loss. Longitudinal studies will determine whether these changes precede alterations detectable by neuroimaging.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641848     DOI: 10.1016/j.parkreldis.2011.04.014

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.

Authors:  Andreas Puschmann; Elisabet Englund; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Anna-Lena Törnqvist; Stig Rehncrona; Håkan Widner; Zbigniew K Wszolek; Matthew J Farrer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2011-12-06       Impact factor: 4.891

Review 2.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

3.  Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

Authors:  Avner Thaler; Anat Mirelman; Tanya Gurevich; Ely Simon; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Nir Giladi
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

Review 4.  Olfactory dysfunction in Parkinson disease.

Authors:  Richard L Doty
Journal:  Nat Rev Neurol       Date:  2012-05-15       Impact factor: 42.937

5.  Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.

Authors:  Claustre Pont-Sunyer; Alex Iranzo; Carles Gaig; Ana Fernández-Arcos; Dolores Vilas; Francesc Valldeoriola; Yaroslau Compta; Ruben Fernández-Santiago; Manel Fernández; Angels Bayés; Matilde Calopa; Pilar Casquero; Oriol de Fàbregues; Serge Jaumà; Victor Puente; Manel Salamero; Maria José Martí; Joan Santamaría; Eduard Tolosa
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

6.  Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.

Authors:  Adamantios Mamais; Meera Raja; Claudia Manzoni; Sybille Dihanich; Andrew Lees; Darren Moore; Patrick A Lewis; Rina Bandopadhyay
Journal:  Neurobiol Dis       Date:  2013-06-05       Impact factor: 5.996

7.  Effect of dual-task interference on the hand flexibility of patients with Parkinson's disease carrying the leucine-rich repeat kinase 2 gene mutation.

Authors:  Guangan Zhou; Shen Yang; Tuanzhi Chen; Piu Chan; Yifeng DU
Journal:  Exp Ther Med       Date:  2013-10-18       Impact factor: 2.447

8.  Non-motor and motor features in LRRK2 transgenic mice.

Authors:  Zoë Bichler; Han Chi Lim; Li Zeng; Eng King Tan
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

9.  Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

Authors:  Jan O Aasly; Krisztina K Johansen; Gunnar Brønstad; Bjørg J Warø; Nour K Majbour; Shiji Varghese; Fatimah Alzahmi; Katerina E Paleologou; Dena A M Amer; Abdulmonem Al-Hayani; Omar M A El-Agnaf
Journal:  Front Aging Neurosci       Date:  2014-09-25       Impact factor: 5.750

10.  CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.

Authors:  Nour K Majbour; Jan O Aasly; Eldbjørg Hustad; Mercy A Thomas; Nishant N Vaikath; Naser Elkum; Wilma D J van de Berg; Takahiko Tokuda; Brit Mollenhauer; Henk W Berendse; Omar M A El-Agnaf
Journal:  Transl Neurodegener       Date:  2020-05-06       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.